The discovery of the Bombali virus in Sierra Leone's bats marks a significant breakthrough for the PREDICT project, which aims to find viruses before they spillover into humans. The finding suggests that bats are likely hosts of ebolaviruses and underscores the importance of understanding their role in preventing Ebola outbreaks.
A study published in PLOS Pathogens reveals that two types of human antibodies synergize to inhibit different steps of Ebola virus infection. Antibody cocktails combining complementary antiviral effects are proposed as a potential treatment strategy.
The Central Africa region is experiencing rapid urbanization and economic growth, making it more vulnerable to explosive infectious disease outbreaks. The authors note that efforts to build up health care infrastructure are critically needed to mitigate or prevent a large outbreak of Ebola or other infectious diseases in the region.
Scientists have discovered how enveloped viruses, such as HIV and influenza, undergo critical structural changes before infecting host cells. The study used nano-infrared spectroscopic imaging to examine the virus's behavior in simulated cell environments and identified an antiviral compound that can block these changes.
Experts review current Ebola vaccine candidates and clinical trials, highlighting key gaps in knowledge that need to be addressed by future research. More data is needed on the durability and rapidity of immune responses generated by various vaccine approaches.
Researchers found a new approach to stop Ebola virus by disabling its infection machinery and boosting the immune system. Nine antibodies that protect mice without neutralizing in test tubes were identified, offering hope for therapeutic cocktails.
A new study by Texas Biomedical Research Institute sheds light on the role of specific proteins in triggering autophagy, a mechanism allowing Ebola virus to enter cells. The findings have implications for treating complex diseases such as cancer and Alzheimer's, where macropinocytosis is dysregulated.
Researchers found that Ebola outbreaks have a lasting negative impact on Liberian agricultural production, income, and food security. Despite no difference in annual household income between affected and unaffected areas, communities with EVD experienced greater crop production losses.
Researchers at Vanderbilt University Medical Center have isolated two potent monoclonal antibodies that efficiently neutralized the Zaire, Sudan, and Bundibugyo ebolaviruses. These antibodies also showed protection against infection in animal models, offering a promising lead for the development of injectable antibody treatments.
A recent study led by Georgia State University identifies a gene from Ebola virus in myotis bats, which has been adapted to regulate their own immune response. The researchers found that the gene is attenuated in its ability to inhibit the immune response, but shares a similar structure with the Ebola VP35 protein.
A study found that Myotis bats have integrated viral proteins produced by Ebola into their genomes, resulting in less potent immune suppressors. This suggests that bats may have co-opted these proteins for immune function, potentially reducing their susceptibility to viral infections.
A study found that bats have preserved a viral gene from an ancient Ebola-like virus for millions of years. The VP35 gene helps regulate the immune system and may play a role in preventing disease in bats.
A flare-up of an Ebola infection in a woman who had survived the disease a year earlier has highlighted the need for continued surveillance and strengthened health systems. The virus was detected in her family members, including her husband and sons, through genetic analysis.
Researchers identified cytotoxic T cell responses to Ebola-specific proteins in 26 Sierra Leonean survivors, suggesting a vaccine targeting both viral nucleoprotein and glycoprotein could elicit cell-mediated immunity. The study provides insights into the immune response of Ebola survivors and potential strategies for vaccine development.
A new Scripps Research study found that nearly all Ebola survivors had killer T cells responding to the nucleoprotein, while only a minority responded to the glycoprotein. This discovery suggests a more effective vaccine strategy by targeting both proteins.
Scientists have discovered a set of powerful broadly neutralizing antibodies in the blood of Ebola survivors, providing substantial protection against disease caused by three Ebola virus species. The researchers hope that these antibodies will serve as promising candidates for further development as therapeutic molecules.
Lehigh University researchers aim to block specific virus entry while preserving normal cellular processes, which is a principal difficulty in designing therapies against viruses. The Ebola virus infects healthy cells by disguising itself as debris, prompting the need for accurate understanding of virus uptake processes.
Dr. Christopher Basler and his team will study Reston ebolavirus (Reston virus), a virus that resembles Ebola but does not cause disease in humans. They aim to better understand the virus's mechanisms of replication, animal disease severity, and potential ways to reduce its deadly effects.
Researchers found Ebola survivors in Sierra Leone suffered from a range of neurological disorders, including migraines and stroke. The study suggests that these patients require specialist support and treatment to manage their symptoms.
Scientists at Tufts University visualized the flu virus's dynamic surface protein structure that reaches out to hijack target cells, revealing a 'better mousetrap' mechanism. The discovery sheds new light on viral entry and may help develop more effective vaccines.
A Penn study found that protein fragments in semen enhance Ebola virus transmission and protect the virus from environmental stress. Researchers suggest targeting amyloids could prevent sexual transmission of the Ebola virus.
Researchers created a genetic family tree of the Ebola epidemic, revealing its spread between 2013-2016. Closing international borders proved effective in slowing down the virus, while local measures had little impact.
A recent study found the Alkhurma hemorrhagic fever virus in ticks collected from migrating birds in the Mediterranean basin. The discovery suggests that birds may contribute to the spread of the virus to new geographical areas. Continuing surveillance is essential to understand the ecology of the virus and prevent its potential spread.
Researchers analyzed WASH and IPC data from two Ebola treatment centers in Sierra Leone, finding strong correlations between patient population size, disinfectant usage, and personal protective equipment use. The study's findings can aid planning and management of facilities for future Ebola outbreaks.
A Phase 1 clinical trial is evaluating the safety and tolerability of mAb114, a single monoclonal antibody developed from an Ebola survivor. The trial aims to enroll 18-30 healthy volunteers and will not expose participants to Ebola virus.
Researchers have created a modeling framework that takes a zoonotic perspective on Ebola, predicting the next outbreak by tracking bat migration patterns and environmental factors. The study suggests that environmental conditions play a key role in the spread of the Ebola virus among bats.
Scientists have identified a molecule found on human cells and some animal cells that could be a useful target for drugs against chikungunya virus infection. Mxra8, a key to the entry of chikungunya virus into host cells, was identified using CRISPR-Cas9.
A new study identifies specific characteristics of Ebola retinal lesions, providing clues on how the virus travels to the retina and causes damage. Researchers found unique retinal scars in 15% of Ebola survivors with reported eye symptoms after recovery.
A University of Kent-led study reveals that prophylactic mass vaccination programs are not effective in preventing new Ebolavirus outbreaks. To establish herd immunity, 80% of the population would need to be immunized, which is currently unachievable.
NIH scientists found that Makona Ebola virus mutations did not impact disease progression or viral shedding in animal models, suggesting a consistent disease presentation. The study also compared EBOV-Makona to the original EBOV-Mayinga strain, finding that Makona is less virulent.
Researchers have identified and studied antibodies from human survivors of Ebola Bundibugyo that neutralize and protect against infection with several different Ebola virus species. The newly discovered antibodies bond at a different site on the Ebola virus than other antibodies currently used to develop Ebola therapies.
A novel marmoset model of human Zika virus infection offers new opportunities for understanding the virus's impact on congenital disease in humans. The researchers found that infection of marmoset dams recapitulates the human infection more faithfully than other animal models.
Researchers have created a modeling framework that considers ecological dimensions driving bat migration patterns to forecast Ebola outbreaks. The tool analyzes spatially distributed random fluctuations of environmental parameters to understand how they impact bat migrations.
A new study led by St. Michael's Hospital maps the potential risk of yellow fever virus spread to cities around the world, analyzing travel patterns and environmental conditions. The research highlights the need for countries to reexamine their policies to prevent yellow fever virus importation, protect travelers, and prevent exportation.
A MU study found that news coverage of Ebola focused on individual stories to humanize those affected, increasing public understanding and awareness. The researchers suggest that reporters covering health crises should consider writing human interest stories that also share helpful information.
Researchers at ETH Zurich found that initial estimates of Ebola's genome change rate were due to biased computer models and limited virus sample data. The team's new calculations show a slower, more accurate mutation rate over time.
Researchers report successful cataract surgeries in 34 Ebola survivors, improving visual acuities from Hand Motions to 20/30 levels. The study provides evidence for safe elective eye surgery in Ebola survivors at risk of uveitis and vision impairment.
A new study reveals that many viruses infecting humans today have ancient evolutionary histories dating back to the first vertebrates, with discoveries made in fish and reptiles. The research, a collaboration between several institutions, found 214 novel RNA viruses in healthy animals, including relatives of Ebola and influenza viruses.
The study found that preprint posting increased during the Zika epidemic compared to the Ebola outbreak, providing earlier access to scientific reports. The authors advocate for broader use of preprints to facilitate criticism, analysis, and further studies in infectious disease outbreaks.
Researchers at Yale University developed a novel RNA-based therapy to target West Nile virus, delivered through the nose. The therapy reduced the virus in the brain and allowed the immune system to destroy it, resulting in a 90% survival rate among treated mice. The treatment also provided long-term protection against future exposure.
Researchers at Georgia State University identified a chemical compound that effectively inhibits the replication of the Ebola virus and several other viruses. The study found benzoquinoline to be a potent antiviral agent with activity against multiple viruses, including Marburg virus and Zika virus.
Researchers at Boston University have discovered a common pattern of immune response among monkeys exposed to Ebola virus, occurring four days before the onset of fever. This finding suggests a possible biomarker for early diagnosis and could lead to better quarantine and control of outbreaks.
Scientists identified potential biomarkers in nonhuman primates exposed to Ebola virus that appeared up to four days before fever onset. These markers could predict disease development prior to other host-based indications of infection.
A new study published in PLOS Medicine found that high doses of antiviral drug favipiravir extended survival in non-human primates infected with Ebola virus. The drug was shown to inhibit viral replication in a drug concentration-dependent manner, with animals treated at higher doses surviving longer than those treated at lower doses.
Researchers at Purdue University may have discovered a way to stop Ebola virus replication by mutating its most important protein, VP40. The study found that altering the amino acid sequence of VP40 reduces lipid binding and prevents viral budding, offering new targets for therapeutics.
A majority of US adults (59.7%) would pay at least $1 for an Ebola vaccine, according to a national survey conducted during the 2014-2016 West African outbreak. Participants who had traveled internationally and were interested in getting vaccinated were more likely to be willing to pay.
A new study using recombinant adeno-associated virus (rAAV) delivery vectors found that ZMapp antibodies administered to mice resulted in 100% protection against Ebola infection. The study also compared different doses and routes of administration, with the best results achieved using a single rAAV-delivered antibody.
University of Alberta researchers have found the Ebola polymerase enzyme, which may lead to more effective research and better treatments for the often fatal infection. The discovery allows for the study of Ebola inhibitors in any lab environment, accelerating the search for antiviral medicines.
Researchers at the University of Guelph have made a breakthrough in combating Ebola with an innovative antibody delivery method. The approach delivers monoclonal antibodies through a viral vector, bypassing the need for a natural immune response, offering 100-per-cent protection against Ebola infection in mice.
Scientists at Texas Biomedical Research Institute are set to test the experimental Ebola treatment ZMapp, which showed a 91% probability of preventing mortality in a previous study. The trial is part of a $2 million contract with Mapp Biopharmaceutical, Inc. and aims to determine the effectiveness of the therapy.
The 2014 Ebola outbreak had a significant impact on Liberia's healthcare system, with a 67.3% drop in clinic visits and 35.2% decrease in first ANC visits four months into the outbreak. However, health system outputs began rebounding by November 2016, with all systems exceeding pre-Ebola forecasted trends for three consecutive months.
Researchers at Lehigh University aim to elucidate the biomechanical mechanism of Ebola-host cell interaction using computational molecular adhesion mechanics and single-molecule force spectroscopy. Their goal is to provide new pharmacological targets for antiviral drug development.
Researchers will collect data from survivors of viral outbreaks to understand how some people fight off the disease. The goal is to inform vaccine design, develop new diagnostics, and prevent future outbreaks.
A study found that Ebola virus infects reproductive organs of macaques, suggesting similar infection in humans. The virus can persist in female reproductive tissues and may reach seminal fluid in men.
Researchers at Hokkaido University identified a key process enabling Ebola virus entry, targeting antiviral drug development.
A new study at WashU Medicine identified specific features of the influenza virus genome that could improve surveillance for pandemic flu. The researchers found that certain strains of the virus require similar genetic material to recombine and create a new hybrid virus.
The study provides the first atomic description of the herpes virus associated with Kaposi's sarcoma, allowing scientists to identify specific targets for antiviral therapies. This breakthrough could lead to the development of new treatments for both KSHV and Epstein-Barr viruses.
Researchers successfully created a synthetic horsepox vaccine that offers protection against the vaccinia virus, which is associated with serious side effects. Mice immunized with the chimeric HPXV developed similar levels of protective antibodies as those inoculated with VACV, but had less severe reactions.
Researchers at The Scripps Research Institute have discovered the workings of a promising treatment for Marburg virus, which has a mortality rate of up to 88 percent. The treatment, MR191, targets a conserved site on the virus and neutralizes it by mimicking the host receptor.
Researchers have discovered a way to prevent the Ebola virus from spreading by inhibiting a specific enzyme that allows it to copy itself. By blocking this enzyme, the virus's ability to produce more infection is reduced, suggesting potential breakthrough in treatment.